REGENXBIO (RGNX) News Today $7.91 -0.29 (-3.54%) Closing price 03/27/2025 04:00 PM EasternExtended Trading$7.91 0.00 (0.00%) As of 03/27/2025 04:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period REGENXBIO Inc. (NASDAQ:RGNX) Shares Sold by Charles Schwab Investment Management Inc.Charles Schwab Investment Management Inc. cut its stake in REGENXBIO Inc. (NASDAQ:RGNX - Free Report) by 16.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 349,730 shares of the biotechnologMarch 28 at 3:11 AM | marketbeat.com5 Reasons To Buy Regenxbio Right NowMarch 26 at 1:06 PM | seekingalpha.comBank of New York Mellon Corp Sells 159,253 Shares of REGENXBIO Inc. (NASDAQ:RGNX)Bank of New York Mellon Corp trimmed its position in REGENXBIO Inc. (NASDAQ:RGNX - Free Report) by 49.7% during the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 161,136 shares of the biotechnology company's stock after selling 159,253 shares during the periodMarch 24, 2025 | marketbeat.comREGENXBIO's (RGNX) Buy Rating Reiterated at Chardan CapitalMarch 23, 2025 | americanbankingnews.comREGENXBIO Inc. (NASDAQ:RGNX) Receives Average Rating of "Moderate Buy" from AnalystsMarch 22, 2025 | americanbankingnews.comREGENXBIO Inc. (NASDAQ:RGNX) Given Average Rating of "Moderate Buy" by BrokeragesREGENXBIO Inc. (NASDAQ:RGNX - Get Free Report) has earned a consensus rating of "Moderate Buy" from the seven ratings firms that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a hold rating and six have given a buy rating to the company. The average 1March 22, 2025 | marketbeat.comREGENXBIO: New Interim Data Reinforces Potential Of RGX-202 - Quick FactsMarch 21, 2025 | nasdaq.comREGENXBIO (NASDAQ:RGNX) Earns "Buy" Rating from Chardan CapitalChardan Capital restated a "buy" rating and set a $52.00 price target on shares of REGENXBIO in a research note on Thursday.March 21, 2025 | marketbeat.comHC Wainwright Has Bullish Forecast for REGENXBIO Q1 EarningsMarch 21, 2025 | americanbankingnews.comWhat is HC Wainwright's Forecast for REGENXBIO Q1 Earnings?REGENXBIO Inc. (NASDAQ:RGNX - Free Report) - HC Wainwright upped their Q1 2025 earnings estimates for shares of REGENXBIO in a research note issued on Monday, March 17th. HC Wainwright analyst Y. Chen now anticipates that the biotechnology company will earn ($1.21) per share for the quarter, up fMarch 20, 2025 | marketbeat.comRegenxbio reports data from Phase I/II portion of the Affinity Duchenne trialMarch 19, 2025 | msn.comREGENXBIO REPORTS POSITIVE BIOMARKER DATA FROM AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPYMarch 19, 2025 | prnewswire.comHC Wainwright Has Lowered Expectations for REGENXBIO (NASDAQ:RGNX) Stock PriceMarch 19, 2025 | americanbankingnews.comBarclays Keeps Their Buy Rating on RegenXBio (RGNX)March 18, 2025 | markets.businessinsider.comREGENXBIO (NASDAQ:RGNX) Given New $34.00 Price Target at HC WainwrightHC Wainwright decreased their price objective on shares of REGENXBIO from $36.00 to $34.00 and set a "buy" rating for the company in a research note on Monday.March 18, 2025 | marketbeat.comREGENXBIO Inc. (NASDAQ:RGNX) Is About To Turn The CornerMarch 17, 2025 | finance.yahoo.comRegenxbio price target lowered to $34 from $36 at H.C. WainwrightMarch 17, 2025 | markets.businessinsider.comREGENXBIO Earnings Results: $RGNX Reports Quarterly EarningsMarch 15, 2025 | nasdaq.comREGENXBIO Inc. (NASDAQ:RGNX) Q4 2024 Earnings Call TranscriptMarch 15, 2025 | msn.comREGENXBIO (NASDAQ:RGNX) Price Target Raised to $24.00Morgan Stanley increased their price target on shares of REGENXBIO from $22.00 to $24.00 and gave the company an "overweight" rating in a report on Friday.March 15, 2025 | marketbeat.comREGENXBIO (NASDAQ:RGNX) Earns Buy Rating from Chardan CapitalChardan Capital reissued a "buy" rating and issued a $52.00 target price on shares of REGENXBIO in a research report on Friday.March 15, 2025 | marketbeat.comREGENXBIO Earnings Call Highlights Strategic ProgressMarch 14, 2025 | tipranks.comREGENXBIO (NASDAQ:RGNX) Releases Earnings Results, Beats Expectations By $0.18 EPSREGENXBIO (NASDAQ:RGNX - Get Free Report) released its quarterly earnings results on Thursday. The biotechnology company reported ($1.01) EPS for the quarter, topping analysts' consensus estimates of ($1.19) by $0.18. REGENXBIO had a negative net margin of 283.19% and a negative return on equity of 70.65%.March 14, 2025 | marketbeat.comRegenxbio at Barclays Healthcare Conference: Strategic Updates and PartnershipsMarch 14, 2025 | investing.comStifel Nicolaus Keeps Their Buy Rating on RegenXBio (RGNX)March 14, 2025 | markets.businessinsider.comRegenXBio (RGNX) Gets a Buy from Bank of America SecuritiesMarch 14, 2025 | markets.businessinsider.comRegenxbio reports Q4 EPS ($1.01), consensus ($1.08)March 14, 2025 | markets.businessinsider.comREGENXBIO Inc. (RGNX) Q4 2024 Earnings Call TranscriptMarch 13, 2025 | seekingalpha.comREGENXBIO Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational UpdatesMarch 13, 2025 | prnewswire.comREGENXBIO Announces Presentations at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific ConferenceMarch 10, 2025 | prnewswire.comREGENXBIO Inc. (NASDAQ:RGNX) Shares Sold by Rhumbline AdvisersRhumbline Advisers lessened its stake in REGENXBIO Inc. (NASDAQ:RGNX - Free Report) by 35.4% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 74,269 shares of the biotechnology company's stock after selliMarch 8, 2025 | marketbeat.comREGENXBIO (NASDAQ:RGNX) Upgraded by StockNews.com to Hold RatingStockNews.com raised REGENXBIO from a "sell" rating to a "hold" rating in a research report on Friday.March 7, 2025 | marketbeat.comREGENXBIO (RGNX) Projected to Post Quarterly Earnings on ThursdayREGENXBIO (NASDAQ:RGNX) will be releasing earnings after the market closes on Thursday, March 13, Financial Modeling Prep reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=670771)March 6, 2025 | marketbeat.comRegenXBio Partners with Nippon Shinyaku for Gene TherapiesMarch 4, 2025 | tipranks.comRegenxbio closes strategic partnership with Nippon ShinyakuMarch 4, 2025 | markets.businessinsider.comREGENXBIO Announces Closing of Strategic Partnership with Nippon Shinyaku for MPS DiseasesMarch 4, 2025 | prnewswire.comY Intercept Hong Kong Ltd Takes $1.06 Million Position in REGENXBIO Inc. (NASDAQ:RGNX)Y Intercept Hong Kong Ltd bought a new position in shares of REGENXBIO Inc. (NASDAQ:RGNX - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 137,402 shares of the biotechnology company's stoFebruary 27, 2025 | marketbeat.comREGENXBIO (NASDAQ:RGNX) Upgraded to Hold at StockNews.comStockNews.com raised REGENXBIO from a "sell" rating to a "hold" rating in a research note on Tuesday.February 26, 2025 | marketbeat.comREGENXBIO to Host Conference Call on March 13 to Discuss Fourth Quarter and Full Year 2024 Financial Results and Recent Operational HighlightsFebruary 26, 2025 | prnewswire.comREGENXBIO to Participate in Upcoming Investor ConferencesFebruary 25, 2025 | prnewswire.comREGENXBIO Inc. (NASDAQ:RGNX) Given Consensus Rating of "Moderate Buy" by BrokeragesShares of REGENXBIO Inc. (NASDAQ:RGNX - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the eleven research firms that are currently covering the company, Marketbeat.com reports. Two investment analysts have rated the stock with a hold recommendation and nine haFebruary 25, 2025 | marketbeat.comFY2024 EPS Estimates for REGENXBIO Cut by Leerink PartnrsREGENXBIO Inc. (NASDAQ:RGNX - Free Report) - Leerink Partnrs lowered their FY2024 EPS estimates for shares of REGENXBIO in a note issued to investors on Wednesday, February 19th. Leerink Partnrs analyst M. Foroohar now forecasts that the biotechnology company will post earnings per share of ($4.9February 24, 2025 | marketbeat.comLeerink Partners Sticks to Their Buy Rating for RegenXBio (RGNX)February 23, 2025 | markets.businessinsider.comREGENXBIO (RGNX) Expected to Announce Quarterly Earnings on TuesdayREGENXBIO (NASDAQ:RGNX) will be releasing earnings before the market opens on Tuesday, February 25, Financial Modeling Prep reports.February 18, 2025 | marketbeat.comREGENXBIO (NASDAQ:RGNX) Lowered to Sell Rating by StockNews.comStockNews.com downgraded REGENXBIO from a "hold" rating to a "sell" rating in a report on Saturday.February 15, 2025 | marketbeat.comGoldman Sachs Downgrades REGENXBIO (RGNX)February 11, 2025 | msn.comGoldman Sachs cuts Regenxbio stock rating, slashes price targetFebruary 11, 2025 | msn.comRegenxbio downgraded to Neutral from Buy at Goldman SachsFebruary 11, 2025 | markets.businessinsider.comRegenXBio (RGNX) was downgraded to a Hold Rating at Goldman SachsFebruary 11, 2025 | markets.businessinsider.comThe Goldman Sachs Group Downgrades REGENXBIO (NASDAQ:RGNX) to NeutralThe Goldman Sachs Group lowered REGENXBIO from a "buy" rating to a "neutral" rating and decreased their price target for the stock from $38.00 to $14.00 in a research note on Tuesday.February 11, 2025 | marketbeat.com Remove Ads Get REGENXBIO News Delivered to You Automatically Sign up to receive the latest news and ratings for RGNX and its competitors with MarketBeat's FREE daily newsletter. Email Address RGNX Media Mentions By Week RGNX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RGNX News Sentiment▼0.640.78▲Average Medical News Sentiment RGNX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RGNX Articles This Week▼114▲RGNX Articles Average Week Remove Ads Get REGENXBIO News Delivered to You Automatically Sign up to receive the latest news and ratings for RGNX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies VERA News GLPG News KNSA News SDGR News AAPG News IDYA News WVE News IMCR News ANIP News DYN News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RGNX) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersA $6.9 Trillion Cash Tsunami Is Coming – Move Your Money NOWExpert: "Prepare For the Mother of All Melt-Ups" In the wake of Wall Street volatility, stock-picking legen...Stansberry Research | SponsoredElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredAI Boom Takes a Shocking Turn…A potentially historic moment for retirement Let's make the most of this market together. Crypto 101 Media | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding REGENXBIO Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share REGENXBIO With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
